false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
Refresher on Selecting Genetic Testing for Ovarian ...
Recording
Recording
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this webinar, Dr. Tom Krivak and Dr. Leah Stender discuss the importance of genetic testing in ovarian cancer treatment decisions. They highlight the guidelines for germline and tumor testing, and emphasize the importance of HRD testing in determining treatment options. Dr. Krivak emphasizes his belief in the utilization of maintenance therapy for all patients with advanced stage ovarian cancer, and discusses the benefits seen in studies that used PARP inhibitors in patients with germline BRCA mutations or HRD-positive tumors. He also highlights the importance of testing in the recurrent setting, noting that the FDA has modified its guidelines to only recommend PARP inhibitors for patients with germline BRCA mutations. Dr. Stender emphasizes the need for standardized testing practices, and discusses the challenges and options in germline and tumor testing. Overall, the webinar underscores the importance of genetic testing in guiding treatment decisions and improving patient outcomes in ovarian cancer.
Keywords
genetic testing
ovarian cancer
treatment decisions
HRD testing
maintenance therapy
PARP inhibitors
germline BRCA mutations
recurrent setting
Contact
education@igcs.org
for assistance.
×